Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings. Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's ...

Vertex Pharmaceuticals Incorporated (Nasdaq ... deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

Gilead Sciences and Inc. Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets ...

Vertex Pharmaceuticals (Vertex) is a biotechnology company that ... Orkambi (ivacaftor/lumacaftor), and Kalydeco (ivacaftor) for treating cystic fibrosis. Through its research and development efforts, ...